Athira Pharma, Inc. Quarterly Debt-to-equity in % from Q2 2021 to Q2 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Athira Pharma, Inc. quarterly Debt-to-equity history and growth rate from Q2 2021 to Q2 2024.
  • Athira Pharma, Inc. Debt-to-equity for the quarter ending June 30, 2024 was 24.1 %, a 171% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q2 2024 24.1 +15.2 +171% Jun 30, 2024
Q1 2024 19 +12.2 +177% Mar 31, 2024
Q4 2023 15.4 +10.1 +189% Dec 31, 2023
Q3 2023 12.4 +8.54 +220% Sep 30, 2023
Q2 2023 8.92 +5.33 +149% Jun 30, 2023
Q1 2023 6.88 +3.64 +112% Mar 31, 2023
Q4 2022 5.32 +2.57 +93.7% Dec 31, 2022
Q3 2022 3.89 +1.47 +60.9% Sep 30, 2022
Q2 2022 3.59 +1.23 +52.3% Jun 30, 2022
Q1 2022 3.24 Mar 31, 2022
Q4 2021 2.74 Dec 31, 2021
Q3 2021 2.42 Sep 30, 2021
Q2 2021 2.35 Jun 30, 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.